Plasma Fractionation Market: Key Drivers, Trends, Growth, Outlook 2024-2033

Overview and Scope

Plasma fractionation refers to the process of integrating manufacturing procedures to isolate the crude fractions that are then refined into specific medicinal products, in a sequential and integrated manner.

Sizing and Forecast

The plasma fractionation market size has grown strongly in recent years. It will grow from $28.95 billion in 2023 to $31.78 billion in 2024 at a compound annual growth rate (CAGR) of 9.8%. The growth in the historic period can be attributed to growing prevalence of hemophilia and immunodeficiency disorders, increased aging population, rising demand for immunoglobulins, expansion of plasma collection centers, growing number of surgical procedures .

The plasma fractionation market size is expected to see rapid growth in the next few years. It will grow to $46.72 billion in 2028 at a compound annual growth rate (CAGR) of 10.1%. The growth in the forecast period can be attributed to rising global healthcare expenditure, growing applications of plasma-derived medicinal products, increasing investment in research and development, demand for plasma in the treatment of neurological disorders, expansion of plasma fractionation facilities. Major trends in the forecast period include development of new fractionation technologies, shift towards albumin and immunoglobulin therapies, rising demand for specialty plasma products, focus on pathogen inactivation technologies, strategic collaborations and partnerships in the plasma industry.

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/plasma-fractionation-global-market-report

Segmentation & Regional Insights

The plasma fractionation market covered in this report is segmented –

1) By Product: Immunoglobulins, Coagulation Factors, Albumin, Protease Inhibitors

2) By Application: Immunology, Hematology, Neurology, Critical Care, Hemato-Oncology, Rheumatology

3) By End User: Hospitals and Clinics, Clinical Research Laboratories, Academic Institutes

North America was the largest region in the plasma fractionation market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the plasma fractionation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=7543&type=smp

Major Driver Impacting Market Growth

The increasing number of chronic diseases is expected to propel the growth of the plasma fractionation market going forward. Chronic diseases are defined as conditions that last 1 year or more and require ongoing medical attention, their examples include diseases such as heart disease, cancer, and diabetes. Treatment of patients with chronic diseases through access to plasma products reduces morbidity, improves the quality of life, and is cost-effective, this will in turn increase the demand for plasma fractionation. For instance, in January 2023, according to a report published by the National Library of Medicine, a US-based agency, the number of individuals aged 50 years and older having one or more chronic illnesses is projected to rise by 99.5%, reaching 142.66 million by 2050, up from 71.522 million in 2020 in the United States. Therefore, increasing cases of chronic diseases are driving the growth of the healthcare analytical testing service market. Therefore, an increasing number of chronic diseases of all ages is expected to propel the plasma fractionation market growth.

Key Industry Players

Major companies operating in the plasma fractionation market report are Baxter International Inc., Bio Products Laboratory Limited, Biotest AG, CSL Limited, Grifols S. A, ADMA Biologics Inc., Green Cross Corporation, Hualan Bioengineering Inc., Intas Pharmaceuticals Ltd., Japan Blood Products Organization, Kedrion S. P. A., Kamada Ltd., LFB Biomedicaments S. A. S, Octapharma AG, ProMetic Life Sciences Inc., Sanquin Plasma Products B. V., Shanghai Raas Blood Products Co. Ltd., Shire PLC, Takeda Pharmaceutical Company, Terumo BCT, Bioverativ Inc., China Biologic Products Holdings Inc., China National Biotec Group, Emergent BioSolutions Inc., Grifols International S. A., Bharat Serum Vaccines Limited, Plasma Therapeutics, Prothya Biosolutions B. V., BioPharma Plasma LLC, BioLife Plasma Services LP

The plasma fractionation market report table of contents includes: